New Initiative for Pneumonia Vaccine
$1.5 billion has been pledged to create the first Advanced Market Commitment (AMC) for a pneumococcal vaccine.
The new model (AMC), will be tested as a pilot to see its effectiveness in promoting development of vaccines and medicines for neglected disease. The pilot will provide 7 to 10 years of funding to support the development of future vaccines against pneumococcal disease and will include provisions to assure the long term sustainable supply and price for the poorest countries.
The AMC for pneumococcal disease will offer an improved market for vaccines now in development. Vaccines are bought only if they meet pre-determined standards of efficacy and safety, and if developing countries ask for them. After 7 to 10 years, the AMC funding is likely to be depleted. The AMC will include terms that help assure a sustained and affordable supply in the long term.